small win: triple agonist stopped being a problem at week 65
small win: triple agonist stopped being a problem at week 65, and the part I actually want to talk about is at the bottom.
The early fullness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
It is a triple agonist at the GLP-1, GIP and glucagon receptors.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
a lot of the confident posting here is extrapolation
a lot of the confident posting here is extrapolation
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
the glucagon component is why the metabolic story reads differently
the TRIUMPH programme is still running, so anything definitive is premature
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
- 1Nothing containing this compound is approved anywhere. Research-use-only…6 comments in this branch · started by u/arne_amankwah